Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin

AIDS. 2001 Jun 15;15(9):1185-7. doi: 10.1097/00002030-200106150-00018.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / blood
  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / immunology
  • AIDS-Related Opportunistic Infections / virology
  • Adult
  • Antibiotics, Antitubercular / adverse effects*
  • Antibiotics, Antitubercular / blood
  • Antibiotics, Antitubercular / pharmacokinetics
  • Antibiotics, Antitubercular / therapeutic use
  • CD4 Lymphocyte Count
  • Consumer Product Safety
  • Drug Therapy, Combination
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / blood
  • HIV Protease Inhibitors / pharmacokinetics
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1* / drug effects
  • HIV-1* / genetics
  • HIV-1* / growth & development
  • Humans
  • Pilot Projects
  • Pyrazinamide / therapeutic use
  • RNA, Viral / blood
  • Rifampin / adverse effects*
  • Rifampin / blood
  • Rifampin / pharmacokinetics
  • Rifampin / therapeutic use
  • Ritonavir / adverse effects*
  • Ritonavir / blood
  • Ritonavir / pharmacokinetics
  • Ritonavir / therapeutic use
  • Tuberculosis / blood
  • Tuberculosis / drug therapy*
  • Tuberculosis / immunology
  • Tuberculosis / virology
  • Viral Load

Substances

  • Antibiotics, Antitubercular
  • HIV Protease Inhibitors
  • RNA, Viral
  • Pyrazinamide
  • Ritonavir
  • Rifampin